Company: XAIR
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021561
Chunk: 26

Company: Beyond Air, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Part I, Item 1
Chunk 26
---
the six months September 30, 2025, the weighted average fair value of options granted was $2.38 per share.

    17

BEYOND
AIR, INC. AND SUBSIDIARIES

NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE
4 STOCKHOLDERS’ EQUITY (continued)

The
following was utilized to calculate the fair value of options on the date of grant:

SCHEDULE
OF FAIR VALUE OF OPTION 

    September
    30, 2025  
    September
    30, 2024 

    Risk-free interest rate 
     3.7
                                            – 4.2% 
     4.3
                                            – 4.5%

    Expected volatility (Beyond Air) 
     91.6
                                            – 96.3% 
     81.4
                                            – 88.5%

    Expected volatility (Beyond Cancer) 
     N/A% 
     N/A%

    Expected volatility (NeuroNos) 
     95.0% 
     -%

    Dividend yield 
     0% 
     0%

    Expected terms (in years) 
     6.25  
     6.25 

The
Company determined that the fair value per share of NeuroNos’ common stock to be $3.00 at the grant date during the six months
ended September 30, 2025 based on the valuation of common stock purchased by external investors during March 2025.

The
following summarizes the components of stock-based compensation expense which included stock options and restricted stock units for the
three and six months ended September 30, 2025 and September 30, 2024 (in thousands):

SCHEDULE
OF STOCK-BASED COMPENSATION EXPENSE 

    2025  
    2024  
    2025  
    2024 

    Three Months
    Ended  
    Six Months
    Ended 

    September
    30,  
    September
    30, 

    2025  
    2024  
    2025  
    2024 
  
    Research and development 
    $301  
    $384  
    $601  
    $1,014 
  
    General and administrative 
     1,